首页> 外文期刊>American Journal of Perinatology Reports >Successful Management of Pulmonary Arterial Hypertension by Monitoring N-Terminal Pro-B-Type Natriuretic Peptide Serum Levels in a Preterm Infant with Chronic Lung Disease: A Case Report
【24h】

Successful Management of Pulmonary Arterial Hypertension by Monitoring N-Terminal Pro-B-Type Natriuretic Peptide Serum Levels in a Preterm Infant with Chronic Lung Disease: A Case Report

机译:通过监测早产儿慢性肺疾病的N末端Pro-B型利钠肽血清水平成功治疗肺动脉高压:病例报告

获取原文
           

摘要

We measured the serial changes in N-terminal probrain natriuretic peptide (NT-proBNP) levels in a 6-month-old male infant with chronic lung disease (CLD) complicated by pulmonary arterial hypertension (PAH). The patient was born at the 24th week of gestation weighing 695 g. At 1?month after birth, an echocardiogram confirmed the diagnosis of CLD with PAH. He was treated with inhaled nitric oxide (iNO) and oral sildenafil and discharged from the hospital. At 190 days of age, the patient was readmitted to our department because of a viral upper respiratory infection. At 195 days of age, his respiratory condition worsened with pulmonary edema and his NT-proBNP level was determined to be 10,117 pg/mL. The patient was immediately administered iNO, and his respiratory condition improved, and NT-proBNP levels decreased. However, he experienced repeated severe cyanosis attacks. Before the attacks, his NT-proBNP level was??1,000 pg/mL. Therefore, we continuously administered iNO until his NT-proBNP level decreased to??1,000 pg/mL. We safely discontinued iNO administration at 473 days of age. In conclusion, serial change in NT-proBNP is a surrogate marker with prognostic value in patients with PAH associated with CLD.
机译:我们测量了6个月大的慢性肺病(CLD)并发肺动脉高压(PAH)的男婴的N末端脑钠肽(NT-proBNP)水平的系列变化。该患者出生于妊娠第24周,体重695 g。出生后1个月,超声心动图证实了PAH对CLD的诊断。他接受了吸入一氧化氮(iNO)和口服西地那非的治疗,并已出院。在190日龄时,由于病毒性上呼吸道感染,该患者再次进入我们的科室。在195日龄时,他的呼吸状况因肺水肿而恶化,他的NT-proBNP水平确定为10117 pg / mL。患者立即接受iNO治疗,呼吸状况得到改善,NT-proBNP水平降低。但是,他经历了多次严重的紫osis发作。攻击前,他的NT-proBNP水平≥1000pg / mL。因此,我们连续给予iNO直到他的NT-proBNP水平降至≤1000 pg / mL。我们安全地在473天龄时停止了iNO管理。总之,NT-proBNP的系列变化是对伴有CLD的PAH患者具有预后价值的替代指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号